See more : Alkhorayef Water & Power Technologies (2081.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Cardiovascular Systems, Inc. (CSII) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cardiovascular Systems, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- JMT Network Services Public Company Limited (JMT-R.BK) Income Statement Analysis – Financial Results
- Bampsl Securities Limited (BAMPSL.BO) Income Statement Analysis – Financial Results
- Yoho Group Holdings Ltd. (2347.HK) Income Statement Analysis – Financial Results
- Cemtrex Inc. Series 1 Warrant (CETXW) Income Statement Analysis – Financial Results
- Gander Gold Corporation (GAND.CN) Income Statement Analysis – Financial Results
Cardiovascular Systems, Inc. (CSII)
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 236.22M | 258.97M | 236.55M | 248.02M | 217.04M | 204.91M | 178.18M | 181.54M | 136.61M | 103.90M | 82.49M | 78.78M | 64.83M | 56.46M | 58.57M | 15.99M | 441.00K | 834.00K | 726.00K | 0.00 |
| Cost of Revenue | 63.44M | 61.13M | 48.76M | 47.68M | 39.48M | 39.44M | 35.42M | 39.52M | 31.04M | 24.38M | 19.22M | 16.28M | 15.00M | 16.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 172.78M | 197.84M | 187.79M | 200.34M | 177.56M | 165.47M | 142.76M | 142.02M | 105.57M | 79.52M | 63.27M | 62.50M | 49.83M | 40.27M | 58.57M | 15.99M | 441.00K | 834.00K | 726.00K | 0.00 |
| Gross Profit Ratio | 73.14% | 76.39% | 79.39% | 80.78% | 81.81% | 80.75% | 80.12% | 78.23% | 77.28% | 76.53% | 76.71% | 79.34% | 76.86% | 71.32% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 36.72M | 41.06M | 43.36M | 33.46M | 26.76M | 22.91M | 25.93M | 30.98M | 21.07M | 15.22M | 11.37M | 8.94M | 10.28M | 14.68M | 43.31M | 38.30M | 29.18M | 16.28M | 0.00 | 2.52M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 167.70M | 148.57M | 144.10M | 162.54M | 143.68M | 117.99M | 86.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 170.53M | 167.50M | 169.97M | 167.70M | 148.57M | 144.10M | 162.54M | 143.68M | 117.99M | 86.72M | 66.37M | 62.37M | 62.45M | 59.82M | 13.02M | 12.19M | 5.33M | 2.99M | 0.00 | 1.28M |
| Other Expenses | 1.34M | 1.22M | 1.23M | 760.00K | -390.00K | -164.00K | 53.00K | -162.00K | -706.00K | -671.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 208.59M | 209.78M | 214.56M | 201.16M | 175.33M | 167.01M | 188.48M | 174.66M | 139.06M | 101.93M | 77.74M | 71.31M | 72.73M | 74.50M | 56.33M | 50.48M | 34.51M | 19.28M | 0.00 | 3.79M |
| Cost & Expenses | 272.03M | 270.91M | 263.32M | 248.84M | 214.81M | 206.45M | 223.90M | 214.18M | 170.10M | 126.32M | 96.96M | 87.59M | 87.73M | 90.69M | 56.33M | 50.48M | 34.51M | 19.28M | 0.00 | 3.79M |
| Interest Income | 817.00K | 499.00K | 1.74M | 2.44M | 1.33M | 383.00K | 0.00 | 0.00 | 0.00 | -1.62M | 5.00K | 12.00K | 402.00K | 3.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.63M | 1.74M | 1.97M | 1.68M | 1.72M | 500.00K | 0.00 | 23.00K | 1.03M | 1.35M | 2.32M | 1.42M | 1.44M | 2.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.34M | 1.22M | 1.23M | 3.45M | 3.93M | 4.14M | 3.92M | 2.32M | 1.37M | 973.00K | 872.00K | 716.00K | 600.00K | 470.00K | 2.25M | 683.00K | 1.29M | 1.30M | 0.00 | 0.00 |
| EBITDA | -34.46M | -10.72M | -25.54M | -825.00K | 2.23M | -1.54M | -35.35M | -32.64M | -33.49M | -22.42M | -14.47M | -8.81M | -22.33M | -35.07M | -963.00K | -39.07M | -32.78M | -16.68M | 726.00K | -3.79M |
| EBITDA Ratio | -14.59% | -4.14% | -10.80% | -0.33% | 1.03% | -0.75% | -19.84% | -17.98% | -24.51% | -21.58% | -17.54% | -11.18% | -34.44% | -62.12% | -1.64% | -244.37% | -7,431.97% | -1,999.76% | 100.00% | 0.00% |
| Operating Income | -35.81M | -11.93M | -26.77M | -825.00K | -1.70M | -1.54M | -56.08M | -32.64M | -33.49M | -22.42M | -14.47M | -8.81M | -22.90M | -34.23M | 2.24M | -34.49M | -34.07M | -18.44M | 726.00K | -3.79M |
| Operating Income Ratio | -15.16% | -4.61% | -11.32% | -0.33% | -0.78% | -0.75% | -31.47% | -17.98% | -24.51% | -21.58% | -17.54% | -11.18% | -35.32% | -60.63% | 3.82% | -215.75% | -7,725.17% | -2,211.27% | 100.00% | 0.00% |
| Total Other Income/Expenses | -817.00K | -1.24M | -233.00K | 760.00K | 3.54M | -164.00K | 53.00K | -185.00K | -1.80M | -1.62M | -2.32M | 0.00 | 28.00K | 1.31M | 5.45M | 5.26M | 399.00K | -797.00K | 0.00 | 0.00 |
| Income Before Tax | -36.62M | -13.17M | -27.01M | -65.00K | 1.84M | -1.71M | -56.02M | -32.82M | -35.29M | -24.04M | -15.44M | 0.00 | -22.87M | -32.93M | 7.69M | -29.24M | -33.67M | -19.24M | 0.00 | 0.00 |
| Income Before Tax Ratio | -15.50% | -5.09% | -11.42% | -0.03% | 0.85% | -0.83% | -31.44% | -18.08% | -25.83% | -23.14% | -18.72% | 0.00% | -35.28% | -58.31% | 13.13% | -182.86% | -7,634.69% | -2,306.83% | 0.00% | 0.00% |
| Income Tax Expense | 310.00K | 252.00K | 231.00K | 190.00K | 132.00K | 86.00K | 6.39M | -2.30M | -333.00K | 344.00K | 479.00K | 1.60M | 1.01M | -25.12M | -5.45M | -5.25M | 0.00 | 797.00K | 13.95M | 3.76M |
| Net Income | -36.93M | -13.42M | -27.24M | -255.00K | 1.71M | -1.79M | -56.02M | -32.82M | -35.29M | -24.04M | -16.79M | -11.13M | -23.90M | -9.11M | 7.69M | -29.25M | -33.67M | -19.24M | -13.95M | -3.76M |
| Net Income Ratio | -15.63% | -5.18% | -11.51% | -0.10% | 0.79% | -0.87% | -31.44% | -18.08% | -25.83% | -23.14% | -20.35% | -14.12% | -36.87% | -16.14% | 13.13% | -182.94% | -7,634.69% | -2,306.83% | -1,921.49% | 0.00% |
| EPS | -0.94 | -0.35 | -0.79 | -0.01 | 0.05 | -0.06 | -1.72 | -1.04 | -1.25 | -1.11 | -0.93 | -0.70 | -1.62 | -1.13 | 2.90 | -21.03 | -323.00 | -257.79 | -208.20 | -53.01 |
| EPS Diluted | -0.94 | -0.35 | -0.79 | -0.01 | 0.05 | -0.06 | -1.72 | -1.04 | -1.25 | -1.11 | -0.93 | -0.70 | -1.62 | -1.13 | 2.80 | -21.03 | -323.00 | -257.79 | -208.20 | -53.01 |
| Weighted Avg Shares Out | 39.23M | 38.83M | 34.28M | 33.54M | 33.15M | 32.37M | 32.54M | 31.55M | 28.30M | 21.69M | 18.04M | 15.92M | 14.75M | 8.07M | 2.67M | 1.39M | 104.24K | 74.63K | 67.00K | 70.97K |
| Weighted Avg Shares Out (Dil) | 39.23M | 38.83M | 34.28M | 33.54M | 33.61M | 32.37M | 32.54M | 31.55M | 28.30M | 21.69M | 18.04M | 15.92M | 14.75M | 8.07M | 2.77M | 1.39M | 104.24K | 74.63K | 67.00K | 70.97K |
Cardiovascular Systems, Inc. to Participate in Two November Healthcare Conferences
Cardiovascular Systems, Inc. (CSII) Q1 2023 Earnings Call Transcript
Cardiovascular Systems (CSII) Reports Q1 Loss, Tops Revenue Estimates
Cardiovascular Systems, Inc. Reports Fiscal 2023 First Quarter Financial Results
Cardiovascular Systems, Inc. Reports Fiscal 2023 First Quarter Financial Results
Cardiovascular Systems, Inc. Announces Full Market Release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems
Source: https://incomestatements.info
Category: Stock Reports